All entries for: Adicet Bio

November 8, 2023

Adicet Bio

Negative Outlook

Boston, MA
51-200 employees
51-200 employees

“The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA’s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.”

Disease Area: Oncology
Drug Type: Biologic
August 9, 2023

Adicet Bio

Negative Outlook

Boston, MA
51-200 employees
51-200 employees
Disease Area: Oncology
Drug Type: Biologic
May 9, 2023

Adicet Bio

Negative Outlook

Boston, MA
51-200 employees
51-200 employees
Disease Area: Oncology
Drug Type: Biologic
November 8, 2022

Adicet Bio

Negative Outlook

Boston, MA
51-200 employees
51-200 employees

Concerns on Profitability: “There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. For example, in August 2022, the Inflation Reduction Act of 2022 (the “IRA”) was signed into law… The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates”

Disease Area: Oncology
Drug Type: Biologic
Scroll to Top